Posters

      Sharing and Verifying Systems Toxicology Data via the INTERVALS and sbv IMPROVER Platforms

      Boue, S.
      Conference date
      May 5, 2017
      Conference name
      sbv IMPROVER Epigenomics Challenge 2017
      Link to more information
      Link to more information
      Topic
      Summary

      Large international programs increasingly generate larger and complex toxicology-relevant data sets. Moreover, industrial R&D endeavors may generate even larger amounts of data but are not as proactive in the area of data sharing. Therefore, sharing these industry-owned datasets represents a great opportunity to push forward frontiers of knowledge for the scientific community as a whole. A proof of concept database and website ('INTERVALS') has been developed to share the results from in vivo inhalation studies as well as in vitro studies conducted by Philip Morris International R&D that assess potential Modified Risk Tobacco Products (MRTP). Data modeling took into account the latest standards in terms of data sharing and reproducible research. Given the successful development of the initial infrastructure, the goal is to grow this initiative to establish a public repository for 21st century pre-clinical systems toxicology MRTP assessment data. In addition, with a goal to maintain scrutiny in data analysis and interpretation, we have developed and applied the sbv IMPROVER methodology to verify the output of research processes in the industry. Whereas computational methods are benchmarked using computational challenges, a verification program engaging panels of independent experts confirms the excellence of the scientific methods used and the integrity of the results shared.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.